老人的黃斑部病變保養預防與治療

Prevention, Care and Treatment for Age-Related Maculopathy

老年性黃斑部病變為高齡族群視力喪失的重要原因之一，其盛行率隨年齡顯著上升；此外，台灣因為近視的盛行，近視性黃斑部病變，也是造成中老年族群視覺障礙與失明的重要病因。黃斑部位於視網膜中央，負責精細視覺功能，對代謝變化與血液供應異常極為敏感。隨年齡增長或病理性眼軸延長，脈絡膜變薄、灌流不足與代謝廢物累積，導致隱結形成、視網膜結構破壞及新生血管生成。臨床上，黃斑部病變可分為乾性與濕性類型；乾性病變以慢性退化為主，而濕性病變則因脈絡膜新生血管滲漏，而造成視力快速惡化。光學同調斷層掃描與超廣角眼底攝影的應用，使黃斑部與周邊視網膜病變得以精確評估。抗血管內皮生長因子治療，已顯著改善濕性病變與部分近視性新生血管病灶之視覺預後，而目前乾性病變仍以延緩進展為主要治療目標。近年補體抑制劑、基因治療、細胞治療及視網膜植入裝置的發展，為未來治療提供新方向。及早辨識視覺功能變化、戒菸、規律追蹤與適當醫療介入，對維持高齡與高度近視族群之視覺功能與生活品質，具有關鍵意義。

Age-related macular degeneration (AMD) is a major cause of visual impairment in aging populations, with prevalence increasing markedly with advancing age. Due to the high prevalence of myopia, myopic macular degeneration (myopic maculopathy) represents a significant cause of vision loss among middle-aged and older individuals in Taiwan. The macula, located at the center of the retina, is responsible for high-resolution vision and is particularly vulnerable to metabolic stress and circulatory compromise. With aging or pathological axial elongation, choroidal thinning, impaired perfusion, and accumulation of metabolic byproducts contribute to drusen formation, retinal structural damage, and neovascularization. Clinically, age-related macular degeneration is classified into dry and neovascular forms. Dry disease is characterized by gradual degenerative changes, whereas neovascular disease involves choroidal neovascular leakage and rapid visual deterioration. Advances in ocular imaging, including optical coherence tomography and ultra-widefield fundus imaging, enable precise assessment of macular and peripheral retinal pathology. Anti–vascular endothelial growth factor therapy has substantially improved visual outcomes in neovascular AMD and myopic choroidal neovascularization, allowing many patients to maintain stable or improved visual function. In contrast, current management of dry macular degeneration primarily focuses on slowing disease progression rather than restoring visual acuity. Emerging therapeutic strategies, including complement inhibition, gene therapy, cell-based therapy, and retinal implant technologies, provide promising directions for future intervention. Early recognition of functional visual changes, modification of risk factors such as smoking, regular ophthalmic surveillance, and timely medical treatment are essential for preserving visual function and quality of life in aging and highly myopic populations.